Metabolic Health · Note 07
Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
Survodutide, an investigational glucagon and GLP-1 receptor dual agonist, met its cardiovascular safety endpoint in people with obesity and established or high-risk cardiovascular disease.
GLP-1 receptor agonists have moved from glucose control into weight management and cardiovascular risk reduction. The next generation adds a second hormone receptor, glucagon, which may increase energy expenditure and improve liver fat as well as appetite control.
Survodutide is a dual glucagon and GLP-1 receptor agonist. In the trial described, it met its cardiovascular safety endpoint in people with obesity and established cardiovascular disease, chronic kidney disease or elevated cardiovascular risk. Cardiovascular safety is a regulatory requirement for obesity therapies, and meeting it is a prerequisite for wider use.
Safety is not the same as benefit. The trial was designed to show that the drug does not increase cardiovascular events, not that it reduces them. Gastrointestinal side effects are common with this class. The full results should be read for the event rates, discontinuation and the specific population enrolled.
Keep in mind
- It met the cardiovascular safety endpoint in a high-risk obesity population.
- Safety non-inferiority does not prove cardiovascular benefit.
Source and reuse
This is an independent editorial summary written for Heartline. It is not a verbatim reproduction and does not reproduce paywalled text. Reporting, data and quotations belong to MedPage Today Cardiology. Read the original at the link provided.
Metadata basis: the publisher’s public RSS feed and the abstract it exposes. Where the full article could not be accessed, this note is explicitly metadata-based and limited to what the feed disclosed. It is not medical advice.
Read the original at MedPage Today Cardiology →